Lilly’s CYRAMZAâ„¢ (ramucirumab) Becomes First FDA-Approved Treatment for Advanced Gastric Cancer After Prior Chemotherapy

[PR Newswire] – INDIANAPOLIS, April 21, 2014 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZAâ„¢ (ramucirumab) as a single-agent treatment … more

View todays social media effects on LLY

View the latest stocks trending across Twitter. Click to view dashboard

See who Eli is hiring next, click here to view